The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1679
ISSUE1679
June 26, 2023
Fezolinetant (Veozah) for Menopausal Vasomotor Symptoms
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Fezolinetant (Veozah) for Menopausal Vasomotor Symptoms
June 26, 2023 (Issue: 1679)
Fezolinetant (Veozah – Astellas), a first-in-class
neurokinin 3 (NK3) receptor antagonist, has been
approved by the FDA for treatment of moderate to
severe vasomotor symptoms (VMS) due to menopause.
It is the second nonhormonal treatment to be...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.